SIGA Technologies is a specialty pharmaceutical company that develops and sells antiviral medicines focused on biodefense. Its lead product, TPOXX, comes in oral and intravenous (IV) formulations and ...
Nguyen indicated ongoing engagement with the U.S. government for future TPOXX procurement and noted, "we expect multiple international sales in 2026" based on current stakeholder interest. The company ...
GAAP revenue reached $81.1 million in Q2 2025, driven by large U.S. government TPOXX deliveries. Operating income soared to $45.7 million in Q2 2025, reflecting shifts in product mix. A special $0.60 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback